Mavzhuda К. Davlatova
A5095774294- Cancer Immunotherapy and Biomarkers
- Renal cell carcinoma treatment
- Economic and Financial Impacts of Cancer
- Bladder and Urothelial Cancer Treatments
Republican Clinical Hospital of the Ministry of Health of the Republic of Tatarstan
2024
Aim To evaluate the safety and toxicity of lenvatinib with pembrolizumab in unselected patients advanced renal cell carcinoma (RCC).
 Materials methods. The Russian phase IV observational study included 151 RCC who received a standard dose regimen 36 clinical centers Federation. Most were diagnosed clear (n=145, 96.0%), synchronous (n=77,51.0%) metastasesof more than one location (n=111,73.5%), removed primary tumor (n=98, 64.9%) classified into intermediate poor IMDC prognostic groups...
Objective: to re-evaluate the efficacy and safety of lenvatinib with pembrolizumab in unselected Russian renal cell carcinoma (RCC) patients, included phase IV study, a median follow-up extended 17.1 months. The primary end point was progression-free survival (PFS), secondary points were overall (OS), objective response rate (ORR) duration (DOR), disease control (DCR) its duration, as well safety. Materials methods. study medical data 165 patients verified advanced RCC who received 36...